GlassScriptPhysician profile
Jay M Nfonoyim
NPI 1386756906
$3,854.99
in general payments reported to CMS, 2019-2025
19 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $350 · 2021: $297 · 2022: $479 · 2023: $548 · 2024: $768 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $790.83 | 2019-2025 | Zerbaxa, Recarbrio, Verquvo |
| Pfizer INC. | $433.24 | 2019-2020 | |
| Amgen INC. | $385.36 | 2019-2025 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $371.67 | 2024-2025 | Zeposia |
| Abbvie INC. | $273.17 | 2021-2024 | |
| Kyowa Kirin, INC. | $260.17 | 2023-2024 | Nourianz |
| Horizon Therapeutics Plc | $237.45 | 2022-2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $218.57 | 2019-2024 | Austedo Xr |
| Shionogi INC | $174.19 | 2021-2025 | Fetroja |
| Banner Life Sciences, LLC | $124.91 | 2022 | |
| Emd Serono, INC. | $124.36 | 2023 | Mavenclad |
| Vanda Pharmaceuticals INC. | $120.91 | 2025 | Ponvory |
| Neurocrine Biosciences, INC. | $119.91 | 2022 | |
| Biogen, INC. | $100.00 | 2023 | Tysabri |
| Ambu INC. | $61.41 | 2020-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $23.62 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
| Astrazeneca Pharmaceuticals LP | $18.89 | 2023 | Andexxa |
| Actelion Pharmaceuticals US, INC. | $16.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Nfonoyim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.